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Increased Set1 binding at the promoter
induces aberrant epigenetic alterations
and up-regulates cyclic adenosine
5'-monophosphate response element
modulator alpha in systemic lupus
erythematosus
Qing Zhang1, Shu Ding2, Huilin Zhang3, Hai Long1, Haijing Wu1, Ming Zhao1, Vera Chan4, Chak-Sing Lau4
and Qianjin Lu1*
Abstract
Background: Up-regulated cyclic adenosine 5'-monophosphate response element modulator α (CREMα) which can
inhibit IL-2 and induce IL-17A in T cells plays a critical role in the pathogenesis of systemic lupus erythematosus
(SLE). This research aimed to investigate the mechanisms regulating CREMα expression in SLE.
Results: From the chromatin immunoprecipitation (ChIP) microarray data, we found a sharply increased H3 lysine 4
trimethylation (H3K4me3) amount at the CREMα promoter in SLE CD4+ T cells compared to controls. Then, by ChIP
and real-time PCR, we confirmed this result. Moreover, H3K4me3 amount at the promoter was positively correlated
with CREMα mRNA level in SLE CD4+ T cells. In addition, a striking increase was observed in SET domain containing
1 (Set1) enrichment, but no marked change in mixed-lineage leukemia 1 (MLL1) enrichment at the CREMα
promoter in SLE CD4+ T cells. We also proved Set1 enrichment was positively correlated with both H3K4me3
amount at the CREMα promoter and CREMα mRNA level in SLE CD4+ T cells. Knocking down Set1 with siRNA in
SLE CD4+ T cells decreased Set1 and H3K4me3 enrichments, and elevated the levels of DNMT3a and DNA
methylation, while the amounts of H3 acetylation (H3ac) and H4 acetylation (H4ac) didn’t alter greatly at the
CREMα promoter. All these changes inhibited the expression of CREMα, then augmented IL-2 and down-modulated
IL-17A productions. Subsequently, we observed that DNA methyltransferase (DNMT) 3a enrichment at the CREMα
promoter was down-regulated significantly in SLE CD4+ T cells, and H3K4me3 amount was negatively correlated
with both DNA methylation level and DNMT3a enrichment at the CREMα promoter in SLE CD4+ T cells.
Conclusions: In SLE CD4+ T cells, increased Set1 enrichment up-regulates H3K4me3 amount at the CREMα
promoter, which antagonizes DNMT3a and suppresses DNA methylation within this region. All these factors induce
CREMα overexpression, consequently result in IL-2 under-expression and IL-17A overproduction, and contribute to
SLE at last. Our findings provide a novel approach in SLE treatment.
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Background
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease which multiple pathogenic mechanisms
are involved in [1, 2]. Recently, accumulating studies
have documented that epigenetic alterations in certain
genes of T cells play critical roles in the pathogenesis of
SLE [3, 4]. Epigenetics refers to heritable changes in
gene expression without changes in the DNA sequence
[5, 6]. The epigenetic mechanisms include mainly DNA
methylation, histone modifications, noncoding RNA regu-
lation, and chromatin modifications [5, 7]. It has been
proved that DNA methylation is hallmark of gene silen-
cing [8], while H3 lysine 4 trimethylation (H3K4me3), H3
acetylation (H3ac), and H4 acetylation (H4ac) are all cor-
related with transcriptional activation [9–11]. As one of
the most familiar histone modifications, H3K4me3 is al-
ways a focus of epigenetics. It accumulates predominantly
at the promoters and early transcribed regions of active
genes, and is involved in transcription initiation, elong-
ation and RNA processing by interacting with RNA poly-
merase II [12, 13]. It also can recruit and/or stabilize
chromatin-remodeling enzymes and transcriptional cofac-
tors [14, 15]. Interestingly, H3K4me3 is able to inhibit
DNA methylation by antagonizing DNA methyltransfer-
ase (DNMT) 3a [16], and augment histone acetylation by
interacting with histone acetyltransferases (HATs) [17]. As
we all know, histone methyltransferases (HMTs) SET do-
main containing 1 (Set1) and mixed-lineage leukemia 1
(MLL1) can both catalyze trimethylation of H3K4 [18, 19].
Set1 and MLL1 are both large proteins containing one
C-terminal SET domain that is associated with an
intrinsic histone lysine-specific methyltransferase activity
[20–22]. They are present, respectively, as the catalytic
subunit and central element of multi-protein H3K4
methyltransferase complexes named complex of proteins
associated with Set1 (COMPASS) and COMPASS-like
[23–25]. Besides the catalytic Set1/MLL1 subunit, COM-
PASS/COMPASS-like contains several other proteins.
Set1/MLL1 protein alone possesses very weak HMT ac-
tivity, and their full activities require the context of the
whole complexes [26, 27].
T cells from SLE patients and murine models produce
less IL-2 compared to normal controls, and lower IL-2
level in SLE patients with higher SLE Disease Activity
Index (SLEDAI) [28, 29]. Decreased IL-2 expression
results in impaired generation of cytotoxic responses,
reduced number and function of T regulatory cells
(Tregs), and defective activation-induced cell death
(AICD). In SLE patients, various cytotoxic responses
have been reported ineffective and may account for the
increased susceptibility to infection. The inhibited Tregs
are unable to prevent autoimmunity, and the deficiency
in AICD may lead to extended survival of autoreactive T
cells, thereby B cells overactivate, in the end, resulting in
overproduction of autoantibodies and the development
of SLE [30–32].
Contrary to IL-2, T cells from patients with SLE and
SLE murine models produce higher amounts of IL-17A,
and IL-17A level is positively correlated with disease ac-
tivity of SLE and titer of anti-dsDNA. Concordantly, in-
hibition of IL-17A can decrease the manifestations of
lupus [33–36]. IL-17A is able to interact with various
chemokines and cytokines, consequently triggers pro-
found proinflammatory responses. It also stimulates B
cells to proliferate and product more antibodies (includ-
ing total IgG, anti-DNA and anti-histone antibodies) [28,
37, 38]. All these contribute to the onset of SLE.
Among the factors that regulate IL-2 and IL-17A, the
cyclic adenosine 5'-monophosphate (cAMP) response
element modulator α (CREMα) plays crucial roles in
SLE. It has been reported that CREMα is increased in T
cells from SLE patients, and the CREMα promoter activ-
ity is positively correlated with SLE disease activity [29].
The overexpression of CREMα can suppress TCR/CD3ζ
chain transcription, which is able to terminate the T cell
response. It also represses the transcription factor c-fos,
the antigen-presenting cell molecule CD86, and Notch
signaling receptor Notch-1 to participate in the patho-
genesis of SLE [35, 39–41]. And, the most important
mechanism is that overexpressing CREMα can repress
IL-2, yet increased IL-17A [32, 42]. However, which fac-
tors and mechanisms contribute to increased CREMα in
SLE T cells remain unclear.
Through methylated CpG-DNA immunoprecipitation
(MeDIP), Hedrich CM et al. found that DNA methyla-
tion level at the CREMα promoter in SLE CD4+ T cells
is lower than healthy controls; moreover, CREMα pro-
moter methylation is reduced in SLE patients who were
in active stage compared to the patients in remission
[29]. By chromatin immunoprecipitation (ChIP) micro-
array, we found that H3K4me3 enrichment at the
CREMα promoter was significantly higher in SLE CD4+
T cells than in healthy controls. We then confirmed this
result by ChIP and real-time PCR. In addition, a marked
increase in Set1 binding was observed, but no striking
change in MLL1 binding at the CREMα promoter in
CD4+ T cells of patients with SLE. Knocking down Set1
with siRNA in SLE CD4+ T cells resulted in reduced
both Set1 binding and H3K4me3 enrichment at the
CREMα promoter, thus suppressing the expression of
CREMα, and increasing the amount of IL-2, simultan-
eously decreasing the production of IL-17A. We also
found the levels of both DNA methylation and DNMT3a
were elevated, while the concentrations of H3ac and
H4ac did not change greatly within the CREMα pro-
moter in SLE CD4+ T cells whose Set1 was knocked
down. According to this clue, we further verified that
DNMT3a was decreased within the CREMα promoter in
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SLE CD4+ T cells, and H3K4me3 enrichment was nega-
tively correlated with both DNA methylation level and
DNMT3a binding at the promoter. Taken together, these
results provide novel insights into the epigenetic mecha-
nisms that cause SLE.
Methods
Subjects
Twenty SLE patients (age 27.10 ± 6.52 years) were re-
cruited from the out-patient clinics and in-patient
wards of the Second Xiangya Hospital, Central South
University, China. All patients fulfilled at least four of
the SLE classification criteria of the American College
of Rheumatology (ACR) [43]. Relevant clinical infor-
mation of the SLE patients is listed in Table 1.
Twenty healthy donors (age: 28.20 ± 5.21 years) were
recruited from medic staff and graduate students at
the Second Xiangya Hospital. All patients and con-
trols were age- and sex-matched, and written in-
formed consent was obtained from every participant.
This study was approved by the Human Ethics Com-
mittee of the Central South University Second Xiangya
Hospital and was conducted in accordance with the Dec-
laration of Helsinki.
Cell isolation
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by Ficoll-Hypaque density gradient centrifugation
(GE Healthcare), and CD4+ T cells were subsequently
isolated by positive selection using magnetic beads
(Miltenyi), according to the manufacturer’s instruction.
The purity of enriched CD4+ T cells was generally higher
than 95%, as checked by flow cytometry.
ChIP microarray
CD4+ T cells from five SLE patients (relevant clinical in-
formation is listed in Additional file 1: Table S1) and five
age- and sex-matched healthy controls were fixed with
1% formaldehyde for 10 min, then they were lysed by
lysis buffer. Lysates from SLE patients and healthy con-
trols were pooled respectively, and were sent to Capital-
bio (Beijing, China). ChIP microarray quality control,
labeling, hybridization, scanning, and statistical analyze
were carried out by Capitalbio. Anti-H3K4me3 antibody-
precipitated DNA and total DNA (input) were labeled
with Cy5 (red) and Cy3 (green), respectively. Samples
were then cohybridized onto the microarray panels, subse-
quently Cy3/Cy5 ratio images of the microarray were
generated. In these images, diversified color intensities
represented relative H3K4me3 enrichments at various
gene promoters. Compared to control CD4+ T cells, at
least twofold increase or decrease in H3K4me3 enrich-
ments in SLE CD4+ T cells were considered significant.
ChIP and real-time PCR
ChIP assay was performed using a ChIP kit (Millipore),
according to the instruction provided by the manufac-
turer. Briefly, CD4+ T cells were fixed with 1% formalde-
hyde for 10 min, then lysed with lysis buffer. Cell lysates
were sonicated to shear the DNA, subsequently the so-
nicated extracts were clarified by centrifugation. After
preclearing by protein G-agarose beads, antibodies were
added and incubated with the extracts at 4 °C overnight
on a rotator. The next day, protein G-agarose beads
were added and rotated for 1 h at 4 °C to pull down
immunoprecipitated complexes. The complexes were
washed and subsequently eluted with elution buffer.
After reversing cross links between DNA and protein by
heating at 65 °C for 4 h, the DNA was purified and sub-
jected to real-time PCR analysis, and the input DNA
was used as endogenous control. All experiments were
performed three times. The primers for CREMα pro-
moter were: forward 5′-TGGGGAGATAGAGGTTGC
AG-3′ and reverse 5′-CGCCAGAAATCCAATGACTT-
3′. The anti-H3K4me3 antibody, anti-H3ac antibody,
and anti-H4ac antibody were purchased from Millipore,
and the anti-Set1 antibody, anti-MLL1 antibody, and
anti-DNMT3a antibody were from Abcam.
Table 1 Profiles of patients with SLE
Patient Gender Age (years) SLEDAI Medications
1 Female 23 8 Pred 30 mg/d
2 Female 20 6 Pred 20 mg/d
3 Male 38 7 Pred 20 mg/d
4 Female 21 3 None
5 Female 26 12 None
6 Female 28 12 Pred 40 mg/d
7 Female 35 4 HCQ 0.2 g/d
8 Female 19 2 None
9 Female 33 3 Pred 5 mg/d
10 Female 27 2 None
11 Female 32 15 Pred 40 mg/d, TGc 30 mg/d
12 Female 22 4 HCQ 0.2 g/d
13 Female 20 3 Pred 5 mg/d
14 Female 22 10 Pred 30 mg/d, TG 30 mg/d
15 Female 25 0 None
16 Male 40 10 Pred 40 mg/d, HCQ 0.2 g/d
17 Female 30 16 Pred 50 mg/d, TG 30 mg/d
18 Female 26 2 HCQ 0.2 g/d
19 Female 20 8 None
20 Female 35 12 Pred 35 mg/d, HCQ 0.2 g/d
SLEDAI systemic lupus erythematosus, Pred prednisone, HCQ hydroxychloroquine,
TG tripterygium glycoside
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RNA extraction and real-time RT-PCR
Total RNA was isolated from CD4+ T cells using TRIzol
Reagent (Invitrogen) according to the protocol provided
by the manufacturer, and stored at −80 °C. Real-time
RT-PCR was performed with a Rotor-Gene3000 thermo-
cycler (Corbett Research), and mRNA level was quanti-
fied by a SYBR PrimeScript RT-PCR kit (Takara). β-actin
was amplified simultaneously as an endogenous control.
Negative control (using water instead of RNA) was also
run for every experiment. All reactions were run in trip-
licate. Primers used were as follows: for CREMα, for-
ward 5’-GAAACAGTTGAATCCCAGCATGATGGAAG
T-3’ and reverse 5’-TGCCCCGTGCTAGTCTGATAT
ATG-3’; for β-actin, forward 5’-CGCGAGAAGATGACC
CAGAT-3’ and reverse 5’-GCACTGTGTTGGCGTACA
GG-3’.
Transfection
Control-siRNA and Set1-siRNA were all designed and
synthesized at Guangzhou RiboBio in China. SiRNA
transfections were performed with a Human T Cell
Nucleofector kit and a nucleofector (Amaxa), accord-
ing to the protocols provided by the manufacturer.
The transfected CD4+ T cells were then cultured in
human T cell culture medium containing 10% fetal
bovine serum (FBS). 24 h after transfection, the cells
were stimulated with 5.0 μg/ml anti-CD3 and 2.5 μg/
ml anti-CD28 antibodies for 48 h, in order to activate
CD4+ T cells. Whereafter, they were subjected to fur-
ther analysis.
Western blotting
CD4+ T cells were lysed with whole cell lysis buffer,
and proteins were extracted and separated by SDS-
polyacrylamide gel electrophoresis, then they were trans-
ferred to PVDF membranes (Millipore). The membranes
were blocked in TBST buffer containing 5% non-fat milk,
and incubated overnight at 4 °C with CREMα antibody
(1:500, Abcam), Set1 antibody (1:500, Abcam), or β-actin
antibody (1:1000, Santa Cruz). All experiments were
repeated three times, and relative expression levels were
quantified by Quantity One software (Bio-Rad).
ELISA
IL-2 and IL-17A productions in the supernatants of
stimulated T cells were measured by IL-2 and IL-17A
quantification ELISA kits respectively (Yuanxiang),
both following the manufacturer’s instructions. Three
replicate wells were used for every sample, and all ex-
periments were performed three times. OD values
were read at 450 nm for both IL-2 and IL-17A
quantification.
MeDIP and real-time PCR
The methylated CpG-DNA immunoprecipitation assay
was performed following the manufacturer’s instruction
(Abcam). Briefly, cells were lysed by lysis buffer, and
DNA was sheared to fragments of 200–1000 bp by son-
ication. After centrifuging, the clear supernatants were
incubated with antibody for 5-methylcytosine or normal
mouse IgG as the negative control. Subsequently, meth-
ylated CpG-DNA was released from immunoprecipitated
complexes. After purifying, the DNA was subjected to
real-time PCR analysis, with input DNA as endogenous
control. All experiments were performed in triplicate.
Statistical analysis
Results were presented as mean ± SD. Values were com-
pared by Student’s t test (paired t test was used to com-
pare data from different transfections, and two-group t
test was used to compare others). Correlations were
measured by Pearson’s correlation coefficient. P values
less than 0.05 were considered significant. All results
were analyzed with SPSS 16.0 software (SPSS Inc.).
Results
Increased H3K4me3 enrichment at the CREMα promoter
in SLE CD4+ T cells in the results of ChIP microarray
We first used ChIP microarray to measure H3K4me3
enrichments at various gene promoters in pooled
CD4+ T cell lysates from SLE patients and healthy
controls. Based on the microarray results, out of the
total 20,832 distinct gene promoters screened, 493
showed a greater than twofold difference in H3K4me3
enrichments between the two groups. Among these,
H3K4me3 enrichment at the CREMα promoter in
SLE CD4+ T cells was 2.48 times higher than in con-
trol CD4+ T cells (Fig. 1a, b).
Increased H3K4me3 enrichment at the CREMα promoter
in SLE CD4+ T cells
In order to verify the finding of ChIP microarray,
ChIP and real-time PCR were performed to measure
H3K4me3 enrichment at the CREMα promoter in CD4+
T cells from 20 SLE patients and 20 healthy controls.
Compared to healthy controls, H3K4me3 enrichment at
the CREMα promoter was significantly increased in SLE
CD4+ T cells (Fig. 2a, Additional file 1: Table S2), consist-
ent with our ChIP microarray result. We further carried
out real-time RT-PCR to examine CREMα mRNA
level in CD4+ T cells from SLE patients, and docu-
mented that H3K4me3 enrichment at the promoter
was positively correlated with CREMα mRNA level in
SLE CD4+ T cells (Fig. 2b).
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Up-regulated Set1 binding at the CREMα promoter in SLE
CD4+ T cells
Overexpression of H3K4me3 at the CREMα promoter in
SLE CD4+ T cells prompted us to evaluate the status of two
H3K4 methyltransferases, Set1 and MLL1. ChIP followed
by real-time PCR was carried out to detect the levels of
Set1 and MLL1 binding at the CREMα promoter in CD4+
T cells from the 20 SLE patients and 20 healthy controls. A
marked increase was identified in Set1 binding at the
CREMα promoter in SLE CD4+ T cells compared with con-
trols (Fig. 3a, Additional file 1: Table S2). However, MLL1
binding at the CREMα promoter did not demonstrate sig-
nificant difference between SLE and control groups (Fig. 3b,
Additional file 1: Table S2). In addition, we confirmed that
the level of Set1 binding was positively correlated with both
H3K4me3 enrichment at the CREMα promoter (Fig. 3c)
and CREMα mRNA level in SLE CD4+ T cells (Fig. 3d).
Down-regulating Set1 in SLE CD4+ T cells inhibits CREMα
expression
To confirm the effect of Set1 on CREMα expression, we
transfected CD4+ T cells from three SLE patients with
Set1-siRNA or control-siRNA. 72 h after transfection,
total amounts of Set1 and CREMα were assessed by West-
ern blotting. As expected, Set1 expression was sharply
inhibited by Set1-siRNA compared to the control-siRNA
group (Fig. 4a, b), and CREMα level was also down-
regulated significantly in CD4+ T cells transfected with
Set1-siRNA (Fig. 4a, b).
Down-regulating Set1 in SLE CD4+ T cells
reduces H3K4me3 enrichment at the promoter of
CREMα
In order to ascertain the mechanism whereby Set1 aug-
ments CREMα expression, we further analyzed Set1 and
Fig. 1 ChIP microarray analysis of H3K4me3 enrichments in SLE and control CD4+ T cells. a ChIP microarray panels showing relative H3K4me3
enrichments at various gene promoters in CD4+ T cell lysates pooled from five healthy controls (left-hand panel) and five patients with SLE
(right-hand panel). Anti-H3K4me3 antibody-precipitated DNA and total DNA (input) were respectively labeled with Cy5 (red) and Cy3
(green), and samples were subsequently cohybridized onto microarray panels. Each individual dot shows the Cy3/Cy5 ratio representing
relative H3K4me3 enrichment at a specific gene promoter. The CREMα promoter dot (indicated by a blue line) is located in the sixteenth
column, seventh row. b Relative H3K4me3 enrichment at the CREMα promoter in SLE and control CD4+ T cells, quantified from the
results shown in (a)
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H3K4me3 binding at the CREMα promoter in the afore-
mentioned SLE CD4+ T cells by ChIP and real-time PCR.
After transfection, Set1 binding at the CREMα promoter
was also reduced together with total Set1 expression in
the Set1-siRNA group (Fig. 4c). Concordantly, H3K4me3
level within the CREMα promoter was decreased after
Set1 down-regulation (Fig. 4d).
Down-regulating Set1 in SLE CD4+ T cells induces IL-2
and inhibits IL-17A
Subsequently, we examined the effects of Set1 under-
expression on IL-2 and IL-17A productions. 72 h after
transfection, supernatant IL-2 and IL-17A concentrations
of the SLE CD4+ T cells were measured by ELISA. Com-
pared to control-siRNA group, we observed significantly
increased IL-2 and deficient IL-17A in the supernatants
collected from Set1-siRNA-transfected CD4+ T cells
(Fig. 4e, f ).
Down-regulating Set1 in SLE CD4+ T cells augments DNA
methylation at the promoter of CREMα
It is well known that H3K4me3 can suppress DNA
methylation and induce histone acetylation [11, 13,
16, 44, 45], so whether the changed H3K4me3 enrich-
ment will alter the levels of DNA methylation and
histone acetylation at the CREMα promoter in SLE
Fig. 2 H3K4me3 enrichment at the CREMα promoter in SLE and control CD4+ T cells. a Relative H3K4me3 enrichment within the CREMα
promoter in SLE and healthy CD4+ T cells was assessed by ChIP and real-time PCR. Results were normalized to input DNA (total chromatin).
b Positive correlation between the levels of H3K4me3 and CREMα mRNA in SLE CD4+ T cells. All reactions were run in triplicate
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CD4+ T cells is still in question. We measured the
quantity of DNA methylation by MeDIP and real-time
PCR, and detected the expressions of H3ac and H4ac by
ChIP and real-time PCR in the siRNA-transfected SLE
CD4+ T cells. Compared with the control-siRNA group,
DNA methylation at the promoter of CREMα in the Set1-
siRNA group was upgraded greatly (Fig. 4g), in addition,
H3ac and H4ac enrichments at this region were both
mildly decreased, but their changes were not significant
(Fig. 4h, i).
Down-regulating Set1 in SLE CD4+ T cells increases
DNMT3a binding at the promoter of CREMα
Since the quantity of DNA methylation is increased at the
promoter of CREMα in these Set1-siRNA-transfected SLE
CD4+ T cells, we further assessed DNMT3a binding at the
region with ChIP and real-time PCR. Consistent with our
finding, the level of DNMT3a was elevated markedly in
Set1-siRNA group (Fig. 4j).
Negatively correlative H3K4me3 enrichment and DNA
methylation level at the CREMα promoter in SLE CD4+
T cells
Hedrich CM et al. have observed that DNA methylation
level at the CREMα promter in SLE CD4+ T cells was
lower than healthy controls [29]. In order to further in-
vestigate the relationship between H3K4me3 and DNA
methylation at the CREMα promoter in SLE CD4+ T
cells, we examined the level of DNA methylation within
the CREMα promoter in CD4+ T cells from the afore-
mentioned 20 SLE patients via MeDIP and real-time
PCR, and proved that H3K4me3 enrichment was nega-
tively correlated with DNA methylation level at the
CREMα promoter in SLE CD4+ T cells (Fig. 5a, Additional
file 1: Table S2).
Decreased DNMT3a binding at the CREMα promoter in
SLE CD4+ T cells
We further assayed the expression of DNMT3a within
the CREMα promoter in CD4+ T cells from the afore-
mentioned 20 SLE patients and 20 healthy controls by
ChIP and real-time PCR. Consequently, we unraveled
that DNMT3a binding at the CREMα promoter was de-
creased greatly in SLE CD4+ T cells (Fig. 5b, Additional
Fig. 3 Set1 and MLL1 binding at the CREMα promoter in SLE and
control CD4+ T cells. a, b Relative levels of Set1 (a) and MLL1 (b)
binding within the CREMα promoter region in SLE and healthy CD4+
T cells were analyzed by ChIP and real-time PCR. Results were
normalized to input DNA (total chromatin). c Positive correlation
between Set1 promoter binding and H3K4me3 level in SLE CD4+ T
cells. d Positive correlation between Set1 promoter binding and
CREMα mRNA level in SLE CD4+ T cells. All experiments were
repeated three times
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Fig. 4 (See legend on next page.)
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file 1: Table S2), and H3K4me3 enrichment was also
negatively correlated with the amount of DNMT3a
(Fig. 5c).
Discussion
In recent years, many researches have focused on the
roles of CREMα in the pathogenesis of SLE, especially
the mechanisms how CREMα inhibits IL-2 and induces
IL-17A. However, the molecular mechanisms causing
CREMα increasing in SLE T cells remain elusive.
By ChIP and real-time PCR, we confirmed our ChIP
microarray finding that H3K4me3 enrichment at the
CREMα promoter in SLE CD4+ T cells was significantly
higher than in healthy controls. Furthermore, we docu-
mented that H3K4me3 enrichment was positively corre-
lated with CREMα mRNA level. These data suggest that
elevated H3K4me3 may be the cause of CREMα up-
regulation in SLE CD4+ T cells. We also proved that
Set1 binding at the CREMα promoter was significantly
increased in SLE CD4+ T cells, and Set1 binding was
positively correlated with both H3K4me3 enrichment
and CREMα mRNA level. However, there was no differ-
ence in MLL1 binding at the CREMα promoter between
CD4+ T cells from SLE patients and healthy controls.
These findings suggest that it is not MLL1, but Set1
overproduction at the CREMα promoter that leads to
H3K4me3 up-regulation, which in turn augments the
expression of CREMα.
Via siRNA-mediated knocking down, we observed that
reducing Set1 in SLE CD4+ T cells down-regulated
CREMα expression and Set1 binding at the CREMα pro-
moter; accordingly, it decreased H3K4me3 enrichment
within the same region, and increased IL-2 concentration,
while inhibited IL-17A production. Together, these results
indicate that Set1 regulates the expression of CREMα, and
this regulation is accomplished at least partly via changing
H3K4me3 enrichment at the CREMα promoter; and the
up-regulated Set1 binding at the promoter augments the
generation of CREMα in SLE CD4+ T cells, subsequently
results in IL-2 reduction and IL-17A overproduction.
Since our manipulations not only altered the amount of
Set1 at the CREMα promoter but also affected total Set1
level, we cannot eliminate the possibility that Set1 also
regulates CREMα, IL-2, and IL-17A in other ways.
In human, DNA can be methylated by DNMTs
(including DNMT1, DNMT3a, and DNMT3b). In this
process, DNMTs catalyze the methyl groups to the 5’-
carbon position of cytosine residues within CpG dinu-
cleotides, forming 5-methylcytosine bases [8]. H3K4
methylation can down-regulate DNA methylation. It is
reported DNMT3a recognizes the unmethylated H3K4
by its ADD domain, subsequently starts de novo DNA
methylation [16]. In mutant strains whose H3K4 methy-
lation is diminished, the DNA methylation expression
increases fivefold [44]. H3K4me3 also interacts with in-
hibitor of growth family member 4 (ING4) of histone
acetyltransferase binding to ORC-1 (HBO1) [10], Yng1
of NuA3 [46], Esa1 of NuA4 [17, 47], and chromo-
ATPase/helicase-DNA binding domain 1 (Chd1) of Spt-
Ada-Gcn5 acetyltransferase (SAGA)/SAGA-like (SLIK)
[17, 48], thereby recruits these HATs to target genes and
enhances their HAT activity. In addition, H3K4me3 can
disrupt binding of the nucleosome remodeling and dea-
cetylase (NuRD) to H3 N-terminal tail, consequently
preventing target gene deacetylation [49]. It is well-
known that DNA methylation can inhibit transcription of
gene by changing the chromatin structure to a more com-
pact and inactive form which blocks the access of some
transcription factors [50]. On the contrary, histone
acetylation can contribute to gene activation through
relaxing the structure of chromatin [10, 11].
We have unraveled that H3K4me3 enrichment at the
CREMα promoter was elevated in SLE CD4+ T cells,
therefore we further investigated whether the levels of
DNA methylation, DNMT3a, H3ac, and H4ac at this
region were affected by the alter of H3K4me3 in these
SLE CD4+ T cells whose Set1 had been knocked down.
We verified that both DNA methylation and DNMT3a
at the promoter were up-regulated, while H3ac and
H4ac enrichments didn’t change significantly.
Hedrich CM et al. have demonstrated that DNA
methylation level at the CREMα promoter in SLE CD4+
T cells was down-regulated [29], and our findings are
consistent with their result. Taken together, all these
data suggested that elevated H3K4me3 at the CREMα
promoter excluded DNMT3a, which consequently lim-
ited DNA methylation at the same region in SLE CD4+
T cells. In order to verify these conclusions, we
(See figure on previous page.)
Fig. 4 Effects of Set1 down-regulation on CD4+ T cells from SLE patients. a, b Relative Set1 and CREMα protein levels were evaluated by western
blotting analysis of SLE CD4+ T cells 72 h after transfection with Set1-siRNA or control-siRNA. β-actin served as an endogenous control. c, d Relative
Set1 (c) and H3K4me3 (d) levels within the CREMα promoter in SLE CD4+ T cells transfected with Set1-siRNA or control-siRNA were confirmed by ChIP
and real-time PCR 72 h after transfection. Results were normalized to input DNA (total chromatin). e, f Relative IL-2 (e) and IL-17A (f) concentrations in
the supernatants of SLE CD4+ T cells were measured by ELISA 72 h after transfection with Set1-siRNA or control-siRNA. g Relative DNA methylation
level at the CREMα promoter in SLE CD4+ T cells transfected with Set1-siRNA or control-siRNA was assayed by MeDIP and real-time PCR 72 h after
transfection. h,i, j Relative enrichments of H3ac (h), H4ac (i), and DNMT3a (j) within the CREMα promoter region in SLE CD4+ T cells were tested by
ChIP and real-time PCR 72 h after transfection with Set1-siRNA or control-siRNA. Results were normalized to input DNA (total chromatin). All experi-
ments were performed in triplicate
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Fig. 5 (See legend on next page.)
Zhang et al. Clinical Epigenetics  (2016) 8:126 Page 10 of 12
measured the amounts of DNA methylation and
DNMT3a within the CREMα promoter. As our expect-
ation, DNMT3a was down-regulated greatly at the
CREMα promoter in SLE CD4+ T cells compared to
healthy controls; moreover, H3K4me3 enrichment was
negatively correlated with both DNA methylation level
and DNMT3a binding at the region in SLE CD4+ T cells.
Conclusions
Our results indicate that Set1 binding at the CREMα
promoter is upgraded in SLE CD4+ T cells, and overex-
pressed Set1 up-regulates H3K4me3 level within the
same region. Elevated H3K4me3 repels DNMT3a, and
subsequently inhibited DNA methylation at the domain.
All these contribute to CREMα overproduction, and
consequently result in IL-2 increasing and IL-17A de-
creasing, ultimately causing the onset of SLE. Our find-
ings indicate that the epigenetic mechanisms contribute
to the development of SLE and provide a novel approach
for the treatment of SLE.
Additional file
Additional file 1: Tables on profiles of SLE patients adopted in ChIP
microarray and relevant results of SLE patients. Table S1. Profiles of SLE
patients adopted in ChIP microarray. Table S2. Relevant results of SLE
patients. (DOC 61 kb)
Abbreviations
ACR: American College of Rheumatology; AICD: Activation-induced cell
death; cAMP: Cyclic adenosine 5'-monophosphate; Chd1: Chromo-ATPase/
helicase-DNA binding domain 1; ChIP: Chromatin immunoprecipitation;
COMPASS: Complex of proteins associated with Set1; CREMα: cAMP response
element modulator α; DNMT: DNA methyltransferase; FBS: Fetal bovine
serum; H3ac: H3 acetylation; H3K4me3: H3 lysine 4 trimethylation; H4ac: H4
acetylation; HAT: Histone acetyltransferase; HBO1: Histone acetyltransferase
binding to ORC-1; HCQ: Hydroxychloroquine; HMT: Histone methyltransferase;
ING4: Inhibitor of growth family member 4; MeDIP: Methylated CpG-DNA
immunoprecipitation; MLL1: Mixed-lineage leukemia 1; NuRD: Nucleosome
remodeling and deacetylase; PBMC: Peripheral blood mononuclear cell;
Pred: Prednisone; SAGA: Spt-Ada-Gcn5 acetyltransferase; Set1: SET domain
containing 1; SLE: Systemic lupus erythematosus; SLEDAI: SLE Disease Activity




This work was supported by grants from the National Natural Science
Foundation of China (No.81301359, No. 81220108017, No. 81430074, No.
81301357, and No. 81373205), the Ph.D. Programs Foundation of Ministry of
Education of China (No. 20120162130003), the Hunan Provincial Natural
Science Foundation of China (No. 14JJ1009), the Project of Innovation-driven
Plan of Central South University (No. 2016CX029), and the National Key
Clinical Specialty Construction Project of National Health and Family Planning
Commission of the People’s Republic of China.
Availability of data and materials
The datasets are available from the corresponding author on reasonable
request.
Authors’ contributions
QZ conducted the sample collection, cell isolation, culture, transfection, ChIP,
real-time PCR, RNA extraction, real-time RT-PCR, Western blotting, ELISA,
MeDIP, statistical analysis, and drafted the manuscript. SD aided in sample
collection and date interpretation. HLZ supervised sample collection and
directed the statistical analysis. HL conducted the ChIP microarray and
analysed its results. HJW helped with the manuscript writing and the final
editing. MZ contributed to funding acquisition and manuscript revision.
VC and CSL helped in editing and review of the manuscript. QJL designed
the study, reviewed the data quality, helped with statistical analyses, and
revised the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Human Ethics Committee of the Central
South University Second Xiangya Hospital and was conducted in accordance
with the Declaration of Helsinki. Written informed consent was obtained
from every participant.
Author details
1Department of Dermatology, Second Xiangya Hospital, Central South
University, Changsha, Hunan 410011, China. 2Department of Dermatology,
Third Xiangya Hospital, Central South University, Changsha, Hunan 410011,
China. 3Emergency Department, Second Xiangya Hospital, Central South
University, Changsha, Hunan 410011, China. 4Division of Rheumatology and
Clinical Immunology, Department of Medicine, The University of Hong Kong,
Hong Kong, China.
Received: 5 August 2016 Accepted: 15 November 2016
References
1. Moulton VR, Holcomb DR, Zajdel MC, Tsokos GC. Estrogen upregulates
cyclic AMP response element modulator alpha expression and
downregulates interleukin-2 production by human T lymphocytes. Mol
Med. 2012;18:370–8.
2. Tenbrock K, Kyttaris VC, Ahlmann M, Ehrchen JM, Tolnay M, Melkonyan H, et
al. The cyclic AMP response element modulator regulates transcription of
the TCR zeta-chain. J Immunol. 2005;175:5975–80.
3. Hewagama A, Richardson B. The genetics and epigenetics of autoimmune
diseases. J Autoimmun. 2009;33:3–11.
4. Pan Y, Sawalha AH. Epigenetic regulation and the pathogenesis of systemic
lupus erythematosus. Transl Res. 2009;153:4–10.
5. Lu Q, Renaudineau Y, Cha S, Ilei G, Brooks WH, Selmi C, et al. Epigenetics in
autoimmune disorders: highlights of the 10th Sjogren’s syndrome
symposium. Autoimmun Rev. 2010;9:627–30.
6. Zhang Q, Long H, Liao J, Zhao M, Liang G, Wu X, et al. Inhibited expression
of hematopoietic progenitor kinase 1 associated with loss of jumonji
domain containing 3 promoter binding contributes to autoimmunity in
systemic lupus erythematosus. J Autoimmun. 2011;37:180–9.
(See figure on previous page.)
Fig. 5 Relationships between H3K4me3, DNA methylation, and DNMT3a. a Negative correlation between H3K4me3 enrichment and DNA
methylation level at the CREMα promoter in SLE CD4+ T cells. b Relative level of DNMT3a binding within the CREMα promoter region in CD4+ T cells
from 20 SLE patients and 20 healthy controls were detected by ChIP and real-time PCR. Results were normalized to input DNA (total chromatin). All
data are representative from three independent experiments. c Negative correlation between H3K4me3 enrichment and DNMT3a binding at the
CREMα promoter in SLE CD4+ T cells
Zhang et al. Clinical Epigenetics  (2016) 8:126 Page 11 of 12
7. Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y. Epigenetics
and autoimmunity. J Autoimmun. 2010;34:J207–19.
8. Zhang P, Su Y, Lu Q. Epigenetics and psoriasis. J Eur Acad Dermatol
Venereol. 2012;26:399–403.
9. Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre
NC, et al. Active genes are tri-methylated at K4 of histone H3. Nature.
2002;419:407–11.
10. Hung T, Binda O, Champagne KS, Kuo AJ, Johnson K, Chang HY, et al. ING4
mediates crosstalk between histone H3 K4 trimethylation and H3
acetylation to attenuate cellular transformation. Mol Cell. 2009;33:248–56.
11. Martin DG, Grimes DE, Baetz K, Howe L. Methylation of histone H3 mediates
the association of the NuA3 histone acetyltransferase with chromatin. Mol
Cell Biol. 2006;26:3018–28.
12. Eissenberg JC, Shilatifard A. Histone H3 lysine 4 (H3K4) methylation in
development and differentiation. Dev Biol. 2010;339:240–9.
13. Zhang X, Bernatavichute YV, Cokus S, Pellegrini M, Jacobsen SE.
Genome-wide analysis of mono-, di- and trimethylation of histone
H3 lysine 4 in Arabidopsis thaliana. Genome Biol. 2009;10:R62.
14. Iberg AN, Espejo A, Cheng D, Kim D, Michaud-Levesque J, Richard S, et al.
Arginine methylation of the histone H3 tail impedes effector binding. J Biol
Chem. 2008;283:3006–10.
15. Gregory GD, Vakoc CR, Rozovskaia T, Zheng X, Patel S, Nakamura T, et al.
Mammalian ASH1L is a histone methyltransferase that occupies the
transcribed region of active genes. Mol Cell Biol. 2007;27:8466–79.
16. Otani J, Nankumo T, Arita K, Inamoto S, Ariyoshi M, Shirakawa M.
Structural basis for recognition of H3K4 methylation status by the
DNA methyltransferase 3A ATRX-DNMT3-DNMT3L domain. EMBO Rep.
2009;10:1235–41.
17. Dehe PM, Geli V. The multiple faces of Set1. Biochem Cell Biol.
2006;84:536–48.
18. Wang P, Lin C, Smith ER, Guo H, Sanderson BW, Wu M, et al. Global
analysis of H3K4 methylation defines MLL family member targets
and points to a role for MLL1-mediated H3K4 methylation in the
regulation of transcriptional initiation by RNA polymerase II. Mol Cell
Biol. 2009;29:6074–85.
19. Yadav S, Singhal J, Singhal SS, Awasthi S. hSET1: a novel approach for colon
cancer therapy. Biochem Pharmacol. 2009;77:1635–41.
20. Lee JS, Shukla A, Schneider J, Swanson SK, Washburn MP, Florens L, et al.
Histone crosstalk between H2B monoubiquitination and H3 methylation
mediated by COMPASS. Cell. 2007;131:1084–96.
21. Lee J, Saha PK, Yang QH, Lee S, Park JY, Suh Y, et al. Targeted
inactivation of MLL3 histone H3-Lys-4 methyltransferase activity in the
mouse reveals vital roles for MLL3 in adipogenesis. Proc Natl Acad Sci
U S A. 2008;105:19229–34.
22. Lee JH, Skalnik DG. CpG-binding protein (CXXC finger protein 1) is a
component of the mammalian Set1 histone H3-Lys4 methyltransferase
complex, the analogue of the yeast Set1/COMPASS complex. J Biol Chem.
2005;280:41725–31.
23. Takahashi YH, Lee JS, Swanson SK, Saraf A, Florens L, Washburn MP, et al.
Regulation of H3K4 trimethylation via Cps40 (Spp1) of COMPASS is
monoubiquitination independent: implication for a Phe/Tyr switch by the
catalytic domain of Set1. Mol Cell Biol. 2009;29:3478–86.
24. Wu M, Wang PF, Lee JS, Martin-Brown S, Florens L, Washburn M, et al.
Molecular regulation of H3K4 trimethylation by Wdr82, a component of
human Set1/COMPASS. Mol Cell Biol. 2008;28:7337–44.
25. Shilatifard A. Molecular implementation and physiological roles
for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol.
2008;20:341–8.
26. Dehe PM, Dichtl B, Schaft D, Roguev A, Pamblanco M, Lebrun R, et
al. Protein interactions within the Set1 complex and their roles
in the regulation of histone 3 lysine 4 methylation. J Biol Chem.
2006;281:35404–12.
27. Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, et al.
Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations
in cell adhesion and growth. Mol Cell Biol. 2007;27:1889–903.
28. Xu WD, Zhang YJ, Wang W, Li R, Pan HF, Ye DQ. Role of CREM in systemic
lupus erythematosus. Cell Immunol. 2012;276:10–5.
29. Hedrich CM, Crispin JC, Rauen T, Ioannidis C, Apostolidis SA, Lo MS, et al.
cAMP response element modulator alpha controls IL2 and IL17A expression
during CD4 lineage commitment and subset distribution in lupus. Proc Natl
Acad Sci U S A. 2012;109:16606–11.
30. Gomez-Martin D, Diaz-Zamudio M, Crispin JC, Alcocer-Varela J. Interleukin
2 and systemic lupus erythematosus: beyond the transcriptional regulatory
net abnormalities. Autoimmun Rev. 2009;9:34–9.
31. Kyttaris VC, Wang Y, Juang YT, Weinstein A, Tsokos GC. CAMP response
element modulator a expression in patients with systemic lupus
erythematosus. Lupus. 2006;15:840–4.
32. Ohl K, Wiener A, Schippers A, Wagner N, Tenbrock K. Interleukin-2
treatment reverses effects of cAMP-responsive element modulator
alpha-over-expressing T cells in autoimmune-prone mice. Clin Exp
Immunol. 2015;181:76–86.
33. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al.
Interleukin 17 acts in synergy with B cell-activating factor to influence B cell
biology and the pathophysiology of systemic lupus erythematosus. Nat
Immunol. 2009;10:778–85.
34. Hedrich CM, Rauen T, Kis-Toth K, Kyttaris VC, Tsokos GC. cAMP-responsive
element modulator alpha (CREMalpha) suppresses IL-17 F protein
expression in T lymphocytes from patients with systemic lupus
erythematosus (SLE). J Biol Chem. 2012;287:4715–25.
35. Lippe R, Ohl K, Varga G, Rauen T, Crispin JC, Juang YT, et al. CREMalpha
overexpression decreases IL-2 production, induces a T(H)17 phenotype and
accelerates autoimmunity. J Mol Cell Biol. 2012;4:121–3.
36. Rauen T, Hedrich CM, Tenbrock K, Tsokos GC. cAMP responsive element
modulator: a critical regulator of cytokine production. Trends Mol Med.
2013;19:262–9.
37. Rauen T, Hedrich CM, Juang YT, Tenbrock K, Tsokos GC. cAMP-
responsive element modulator (CREM)alpha protein induces interleukin
17A expression and mediates epigenetic alterations at the interleukin-
17A gene locus in patients with systemic lupus erythematosus. J Biol
Chem. 2011;286:43437–46.
38. Crispin JC, Tsokos GC. IL-17 in systemic lupus erythematosus. J Biomed
Biotechnol. 2010;2010:943254.
39. Tenbrock K, Juang YT, Leukert N, Roth J, Tsokos GC. The transcriptional
repressor cAMP response element modulator alpha interacts with histone
deacetylase 1 to repress promoter activity. J Immunol. 2006;177:6159–64.
40. Rauen T, Grammatikos AP, Hedrich CM, Floege J, Tenbrock K, Ohl K, et al.
cAMP-responsive element modulator alpha (CREMalpha) contributes to
decreased notch-1 expression in T cells from patients with active systemic
lupus erythematosus (SLE). J Biol Chem. 2012;287:42525–32.
41. Verjans E, Ohl K, Yu Y, Lippe R, Schippers A, Wiener A, et al. Overexpression
of CREMalpha in T cells aggravates lipopolysaccharide-induced acute lung
injury. J Immunol. 2013;191:1316–23.
42. Koga T, Hedrich CM, Mizui M, Yoshida N, Otomo K, Lieberman LA, et al.
CaMK4-dependent activation of AKT/mTOR and CREM-alpha underlies
autoimmunity-associated Th17 imbalance. J Clin Invest. 2014;124:2234–45.
43. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of
the SLEDAI. A disease activity index for lupus patients. The Committee on
Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630–40.
44. Hu JL, Zhou BO, Zhang RR, Zhang KL, Zhou JQ, Xu GL. The N-terminus of
histone H3 is required for de novo DNA methylation in chromatin. Proc
Natl Acad Sci U S A. 2009;106:22187–92.
45. Hazzalin CA, Mahadevan LC. Dynamic acetylation of all lysine 4-methylated
histone H3 in the mouse nucleus: analysis at c-fos and c-jun. PLoS Biol.
2005;3, e393.
46. Taverna SD, Ilin S, Rogers RS, Tanny JC, Lavender H, Li H, et al. Yng1
PHD finger binding to H3 trimethylated at K4 promotes NuA3 HAT
activity at K14 of H3 and transcription at a subset of targeted ORFs.
Mol Cell. 2006;24:785–96.
47. Morillon A, Karabetsou N, Nair A, Mellor J. Dynamic lysine methylation on
histone H3 defines the regulatory phase of gene transcription. Mol Cell.
2005;18:723–34.
48. Pray-Grant MG, Daniel JA, Schieltz D, Yates 3rd JR, Grant PA. Chd1
chromodomain links histone H3 methylation with SAGA- and SLIK-
dependent acetylation. Nature. 2005;433:434–8.
49. Zegerman P, Canas B, Pappin D, Kouzarides T. Histone H3 lysine 4
methylation disrupts binding of nucleosome remodeling and deacetylase
(NuRD) repressor complex. J Biol Chem. 2002;277:11621–4.
50. Li Y, Sawalha AH, Lu Q. Aberrant DNA methylation in skin diseases.
J Dermatol Sci. 2009;54:143–9.
Zhang et al. Clinical Epigenetics  (2016) 8:126 Page 12 of 12
